The two ticagrelor doses each reduced , as compared with placebo , the rate of the primary efficacy end point , with Kaplan-Meier rates at @ years of @ % in the group that received @ mg of ticagrelor twice daily , @ % in the group that received @ mg of ticagrelor twice daily , and @ % in the placebo group ( hazard ratio for @ mg of ticagrelor vs. placebo , @ ; @ % confidence interval -LSB- CI -RSB- , @ to @ ; P = @ ; hazard ratio for @ mg of ticagrelor vs. placebo , @ ; @ % CI , @ to @ ; P = @ ) .